Alector, Poseida and Anchiano propose NASDAQ listings
Alector Inc. (South San Francisco, Calif.), Poseida Therapeutics Inc. (San Diego, Calif.) and Anchiano Therapeutics Inc. (Tel Aviv:ANCN) have proposed to list on NASDAQ.
Alector, which aims to target immune dysfunction to treat neurodegenerative disorders, is seeking up to $150 million in an IPO. In July 2018, the company raised $133 million in series E funding to develop antibodies designed to boost microglial-mediated clearance of disease-associated proteins from the brain. Two of its antibodies with undisclosed targets have reached Phase I testing: AL001 for frontotemporal dementia and AL002 for Alzheimer’s disease. The company hopes to begin clinical trials of two other programs in 2019, and intends to start a Phase II trial of AL001 by 1H20 (see “Manipulating Microglia”)...